參考文獻(xiàn)
1. Fang W, Huang Y, Hong S, et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer[J]. BMC Cancer, 2019, 19(1):595
2. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36-54. doi:10.3978/j.issn.2218-6751.2014.05.01
3. Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179-184. doi:10.1097/JTO.0b013e3182779d18
4. Chong CR, J?nne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389-1400. doi:10.1038/nm.3388
5. Crossland V, et al.The Frequency and Spectrum of EGFR Exon 20 Insertions in NSCLC: A Global Literature Review.J Thorac Oncol 2018;13(10 suppl):S612-S613;
6. Gazdar AF, Minna JD. Inhibition of EGFR signaling: all mutations are not created equal. PLoS Med. 2005;2(11):e377. doi:10.1371/journal.pmed.0020377
7. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28 Suppl 1(Suppl 1):S24-S31. doi:10.1038/onc.2009.198
8. Jorge SE, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res. 2014;47(11):929-939. doi:10.1590/1414-431X20144099
9. Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179-1186. doi:10.1111/cas.12996
10. Lee JK, Shin JY, Kim S, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol. 2013;24(8):2080-2087. doi:10.1093/annonc/mdt127
11. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220-229. doi:10.1158/1535-7163.MCT-12-0620
12. Bazhenova L, Minchom A, Viteri S, Bauml JM, Ou SI, Gadgeel SM, Trigo JM, Backenroth D, Li T, Londhe A, Mahadevia P, Girard N. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021 Dec;162:154-161. doi: 10.1016/j.lungcan.2021.10.020. Epub 2021 Nov 6. PMID: 34818606.
13. Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 8(2):179-184. doi:10.1097/JTO.0b013e3182779d18
14. Yoon S, Lim SM, Jung HA, et al. Clinical Characteristics, Treatment Patterns and Outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC Patients. 2022 ELCC 50P.
15. Hou J, Li H, Ma S, et al. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. Biomark Res. 2022 Apr 13;10(1):21. doi: 10.1186/s40364-022-00372-6.
16. Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and pooled analysis of patient outcomes [published online ahead of print, 2022 May 27]. Curr Med Res pin. 2022;1-34. doi:10.1080/03007995.2022.2083326
17. Kitadai R, Okuma Y. Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers (Basel). 2022;14(10):2519. doi: 10.3390/cancers14102519
18. NCCN Clinical Practice Guidelines in Oncology-Non-small cell lung cancer, version 2[J]. J Natl Compr Canc Netw, 2021
19. 中國(guó)臨床腫瘤學(xué)會(huì)指南工作委員會(huì).2022 CSCO非小細(xì)胞肺癌診療指南[J].人民衛(wèi)生出版社.
20. 楊雪, 趙軍. EGFR外顯子20插入突變陽(yáng)性NSCLC治療的臨床研究進(jìn)展[J]. 中國(guó)肺癌雜志, 2022, 25(5):14.
截至2022年9月20日，Mobocertinib（莫博賽替尼）尚未獲得中國(guó)國(guó)家藥品監(jiān)督管理局（NMPA）批準(zhǔn)，以上信息僅供醫(yī)療衛(wèi)生專業(yè)人士了解學(xué)術(shù)進(jìn)展使用，武田公司不推薦說(shuō)明書外應(yīng)用。
聯(lián)系客服
